SEARCH

SEARCH BY CITATION

References

  • 1
    Marcellin P, Forns X, Goeser T, et al. Virological analysis of patients receiving telaprevir administered Q8H or Q12H with peginterferon-alfa-2A/2B and ribavirin in treatment-naive patients with genotype 1 hepatitis C: Study C208 [AASLD abstract 194]. Hepatology. 2009; 50(suppl):S395A.
  • 2
    McHutchison JG, Manns MP, Muir A, et al. PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferonalfa-2A/B and ribavirin therapy [AASLD abstract 66]. Hepatology. 2009; 50(suppl):S334A.
  • 3
    Kwo PY, Lawitz E, McCone J, et al. Response-guided therapy for boceprevir combination treatment?[AASLD abstract 1582]. Hepatology. 2009; 50(suppl): S1035A.
  • 4
    Kwo PY, Lawitz E, McCone J, et al. High sustained virologic response in genotype 1 null responders to peginterferon alfa-2b plus ribavirin when treated with boceprevir combination therapy [AASLD abstract 62]. Hepatology. 2009; 50(suppl):S331A.

References

  • 1
    Sulkowski MS, Ferenci P, Emanoil C, et al. SILENC1: Early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naïve patient with chronic genotype 1 HCV infection [abstract LB3]. In: Proceedings of the American Association for the Study of Liver Diseases: 60th The Liver Meeting; 2009; Oct. 30-Nov. 3; Boston , MA .
  • 2
    Manns MP, Gane EJ, Rodrigues-Torres M, et al. Early viral response rates in treatment-naïve patients with chronic hepatitic C genotype 1 infection treated with MK-7009 [AASLD abstract 63]. Hepatology. 2009; 50(suppl):332A.
  • 3
    Gane EJ, Roberts SK, Stedman CA, et al. Combination therapy with necleoside polymerase and protease inhibitor in HCV; safety, pharmacokinetics, and virologic results from inform-1 [AASLD abstract 193]. Hepatology. 2009; 50(suppl):394A.
  • 4
    Sulkowski MS, Zeuzem S, Lawitz E, et al. Efficacy and safety of albinterferon alfa-2B in combination with ribavirin in treatment naïve patients with chronic hepatitis C genotype 1 [AASLD abstract 64]. Hepatology. 2009; 50(suppl):333A.
  • 5
    Muir A, Shiffman ML, Zaman A, et al. A phase 1B dose-ranging study of 4 weeks of peg-interferon lambda in combination with ribavirin in patients with chronic genotype 1 hepatics C virus [AASLD abstract 1591]. Hepatology. 2009; 50(suppl): 1039A.